Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in Australia / NCT07286006
Enrolling by invitation Phase 2

A Long-Term Extension Study of IMVT-1402 in Adult Participants With Graves' Disease (GD)

NCT07286006 · tracked via the Priya Life Science Australia tracker
Sponsor
Immunovant Sciences GmbH
Phase
Phase 2
Started
2026-01-26
Last updated
2026-09-29

Condition(s) studied

Graves' Disease

Investigational drug(s) / intervention(s)

IMVT-1402 →

IMVT-1402: Dose 1 for up to 52 weeks

Study summary

This is a long-term extension study that will rollover participants completing feeder studies IMVT-1402-2502 (NCT06727604) or IMVT-1402-2503 (NCT07018323) to evaluate the efficacy and safety of IMVT-1402 in adult participants with GD. Eligible participants will be assigned to 1 of 3 study groups (Groups A, B and C) based on their GD status at the completion of their respective feeder study.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Participants who completed Study IMVT-1402-2502 or Study IMVT-1402-2503. * Other, more specific inclusion criteria are defined in the protocol. Exclusion Criteria: * Have permanently discontinued IMP during the treatment period in the feeder study or have met study stopping criteria at any point up until the end of participation in the feeder study.

Primary outcome measure(s)

  • Percentage of Group A Participants who remain euthyroid, Off ATD, and Off IMVT-1402 — At Week 52

Trial sites (131)

FacilityCityRegionStatus
Site Number - 1561 Phoenix Arizona
Site Number - 1519 Phoenix Arizona
Site Number - 1530 Tucson Arizona
Site Number - 1510 Concord California
Site Number - 1587 Huntington Beach California
Site Number - 1554 Los Angeles California
Site Number - 1588 Orange California
Site Number - 1559 San Francisco California
Site Number - 1558 Santa Clarita California
Site Number - 1552 Torrance California
Site Number - 1533 Aurora Colorado
Site Number -1514 Englewood Colorado
Site Number - 1516 Newark Delaware
Site Number - 1567 Washington D.C. District of Columbia
Site Number - 1556 Clearwater Florida
Site Number - 1522 Doral Florida
Site Number - 1523 Hialeah Florida
Site Number - 1581 Jacksonville Florida
Site Number - 1582 Jacksonville Florida
Site Number - 1505 Miami Florida
Site Number - 1564 Miami Florida
Site Number - 1591 Miami Florida
Site Number - 1590 Ocoee Florida
Site Number - 1508 Orlando Florida
Site Number - 1507 Port Charlotte Florida
Site Number - 1548 West Palm Beach Florida
Site Number - 1566 Atlanta Georgia
Site Number - 1526 Columbus Georgia
Site Number - 1579 Macon Georgia
Site Number - 1518 Stockbridge Georgia
Site Number - 1562 Indianapolis Indiana
Site Number - 1568 Kansas City Kansas
Site Number - 1534 Topeka Kansas
Site Number - 1571 Bowling Green Kentucky
Site Number - 1580 Florence Kentucky
Site Number - 1546 Louisville Kentucky
Site Number - 1589 Metairie Louisiana
Site Number - 1555 New Orleans Louisiana
Site Number - 1565 Baltimore Maryland
Site Number - 1557 Boston Massachusetts

+ 91 more sites — see the full list on the official registry below.

More Immunovant Sciences GmbH trials in Australia

A Study to Assess the Efficacy, Safety, and Tolerability of IMVT-1402 as Treatment for Adult Participants With Graves' Disease Recruiting
Imeroprubart in Adult Participants With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Recruiting

Other trials for the same condition

A Study to Assess the Efficacy, Safety, and Tolerability of IMVT-1402 as Treatment for Adult Participants With Graves' Disease Recruiting
Evaluation of YB-101 for Safety, Tolerability, Pharmacokinetics, and Efficacy in Graves' Disease Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07286006 on ClinicalTrials.gov ↗ ← All trials in Australia